Ion Mobility-Resolved Collision-Induced Dissociation and Electron Transfer Dissociation of N-Glycopeptides: Gathering Orthogonal Connectivity Information from a Single Mass- Selected Precursor Ion Population by Kolli, Venkata et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Faculty Publications -- Chemistry Department Published Research - Department of Chemistry 
2017 
Ion Mobility-Resolved Collision-Induced Dissociation and Electron 
Transfer Dissociation of N-Glycopeptides: Gathering Orthogonal 
Connectivity Information from a Single Mass- Selected Precursor 
Ion Population 
Venkata Kolli 
Katherine N. Schumacher 
Eric Dodds 
Follow this and additional works at: https://digitalcommons.unl.edu/chemfacpub 
 Part of the Analytical Chemistry Commons, Medicinal-Pharmaceutical Chemistry Commons, and the 
Other Chemistry Commons 
This Article is brought to you for free and open access by the Published Research - Department of Chemistry at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Faculty Publications -- 
Chemistry Department by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Ion Mobility-Resolved Collision-Induced Dissociation and 
Electron Transfer Dissociation of N-Glycopeptides: Gathering 
Orthogonal Connectivity Information from a Single Mass-
Selected Precursor Ion Population
Venkata Kolli†, Katherine N. Schumacher†, Eric D. Dodds*
Department of Chemistry, University of Nebraska – Lincoln, Lincoln, NE, 68588-0304, USA
Abstract
Glycopeptide-level mass spectrometry (MS) and tandem mass spectrometry (MS/MS) analyses are 
commonly performed to establish site-specific protein glycosylation profiles that are of central 
importance to gaining structure-function insights on glycoproteins. Confoundingly, the complete 
characterization of glycopeptide connectivity usually requires the acquisition of multiple MS/MS 
fragmentation spectra. Complementary ion fragmentation techniques such as collision-induced 
dissociation (CID) and electron transfer dissociation (ETD) are often applied in concert to address 
this need. While structurally informative, the requirement for acquisition of two MS/MS spectra 
per analyte places considerable limitations upon the breadth and depth of large-scale 
glycoproteomic inquiry. Here, a previously developed method of multiplexing CID and ETD is 
applied to the study of glycopeptides for the first time. Integration of the two dissociation methods 
was accomplished through addition of an ion mobility (IM) dimension that disperses the two 
stages of MS/MS in time. This allows the two MS/MS spectra to be acquired within a few 
milliseconds of one another, and to be deconvoluted in post-processing. Furthermore, the method 
allows both fragmentation readouts to be obtained from the same precursor ion packet, thus 
reducing the inefficiencies imposed by separate CID and ETD acquisitions and the relatively poor 
precursor ion to fragment ion conversion typical of ETD. N-linked glycopeptide ions ranging in 
molecular weight from 1800 to 6500 u were generated from four model glycoproteins that 
collectively encompassed paucimannosidic, high mannose, and complex types of N-glycosylation. 
In each case, IM-resolved CID and ETD events provided complete coverage of the glycan 
topology and peptide sequence coverages ranging from 48.4% (over 32 amino acid residues) to 
85.7% (over eight amino acid residues). The potential of this method for large-scale 
glycoproteomic analysis is discussed.
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One packet of N-glycopeptide precursors can be successively probed by CID and ETD, with 
fragmentation spectra deconvoluted via IM.
Introduction
Glycosylation is the most ubiquitous, diverse, and elaborate form of protein modification; 
accordingly, glycans enzymatically linked to proteins serve highly varied and indispensable 
functions of life.1–4 These include vital contributions to the folding and stability of 
glycoproteins, involvement as essential elements of intermolecular recognition, and action as 
agents of cellular signaling pathways.5–10 Altered protein glycosylation is also a hallmark of 
numerous human diseases, where perturbations in the structures or compositions of protein-
modifying oligosaccharides can either indicate or instigate an unhealthy condition.11–20 The 
foregoing considerations have served to motivate great interest in the detailed 
characterization of glycoproteomic systems; nevertheless, the protein-specific and site-
specific determination of glycosylation profiles is fraught with complexities – both 
biological and technical – and remains well outside the realm of routine analysis.21–24
Despite the challenges involved, mass spectrometry (MS) of proteolytic glycopeptides 
provides a means of associating specific glycan compositions and structures with defined 
positions on the corresponding glycoprotein.25–34 These experiments rely on tandem mass 
spectrometry (MS/MS) methods in order to establish the composition and topology of the 
oligosaccharide, the sequence of the polypeptide, and the site of glycosylation; however, the 
entirety of the glycopeptide connectivity is seldom apparent from any single MS/MS 
spectrum. Thus, the complementarity of multiple ion dissociation methods is frequently 
leveraged in order to garner a more complete structural view.35–42 While the 
photodissociation methods of infrared multiphoton dissociation (IRMPD)43–45 and 
ultraviolet photodissociation (UVPD)46–48 have shown significant potential to acquire 
highly informative MS/MS spectra for glycopeptides, a more common and more widely 
available approach is to pair collision-induced dissociation (CID) and electron transfer 
dissociation (ETD).49–52 This pairing affords a convenient means of capturing both glycan 
connectivity information (via the CID spectrum), as well as peptide sequence and glycosite 
(via the ETD spectrum). When used together to collect complementary fragmentation 
spectra, CID and ETD are generally performed separately, yielding two separate MS/MS 
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spectra. Unfortunately, this comes with the penalty of increased sample consumption and 
reduced duty cycle per analyte characterized.
One approach to multiplexing multiple MS/MS acquisitions involves the incorporation of an 
ion mobility (IM) dimension. In one experiment of this type, IM-resolved precursor ions can 
be subjected to CID as they exit the collision cell. In this so-called “time-aligned parallel” 
dissociation, the ions resulting from post-IM fragmentation appear at the same IM drift time 
as their corresponding precursor ion. This general approach has been applied to an 
assortment of MS/MS analyses, ranging from small molecules to non-covalent protein 
complexes.53–57 Subsequent reports have suggested a similar strategy which integrates CID 
and ETD by IM separation of mass-selected precursor ions that had either undergone an 
electron transfer (ET) reaction or no reaction (NR), followed by vibrational activation (VA).
58, 59 Our laboratory recently reported on the application of this approach to unmodified 
polypeptides of varying molecular weights, and found that complementary sequence 
information could be gathered in much the same manner as acquiring separate CID and ETD 
spectra, yet with higher overall precursor ion utilization efficiency and improved instrument 
duty cycle.60 Given these characteristics, IM-based multiplexed acquisition of CID and ETD 
spectra is rendered a compelling option for high-throughput analysis.
Here, we report the first example of IM-resolved CID and ETD of protonated N-linked 
glycopeptide ions. The analytes considered encompass a wide range of molecular weights, 
charge states, peptide compositions, and glycan structures. In each case, complementary 
fragmentation information was conveyed by high-quality CID and ETD spectra which were 
acquired from the same mass-selected packet of precursor ions. These results suggest that 
the approach is generalizable and provides access to orthogonal structural information for 
even highly challenging N-glycopeptide analyte ions. While these analyses returned similar 
advantages as previously described for analysis of unmodified peptides, we also note that 
this combination of analytical dimensions is capable of delivering additional benefits – 
particularly as IM continues to mature in the areas of oligosaccharide and glycoconjugate 
analysis.61–70
Experimental
Model N-Glycopeptide Preparation.
Four well-characterized glycoproteins were chosen as sources of N-glycopeptides for this 
study: horseradish peroxidase (HRP), bovine ribonuclease B (BRB), coral tree lectin (CTL), 
and bovine serum fetuin (BSF). Proteomics grade trypsin, HRP, BRB, and BSF were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). CTL was purchased from Vector 
Laboratories (Burlingame, CA, USA). For each glycoprotein, a 2 mg/mL solution was 
prepared in 8 M urea with 50 mM ammonium bicarbonate (pH 7.5). A 50 μL portion of this 
denatured glycoprotein solution was combined with 10 μL dithiothreitol (450 mM in 50 mM 
ammonium bicarbonate, pH 7.5; incubated at 55°C for 1 h) followed by 10 μL 
iodoacetamide (500 mM in 50 mM ammonium bicarbonate, pH 7.5; incubated in the dark at 
25°C for 1 h) for disulfide reduction and cysteine alkylation. The mixture was next diluted to 
a total volume of 250 μL with 50 mM ammonium bicarbonate (pH 7.5) to reduce the urea 
concentration to 1.6 M, and treated with 5 μL proteomics grade trypsin (0.5 μg/μL; 
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incubated at 37°C for 18 h). Glycoprotein digests were reduced in volume to approximately 
10 μL by vacuum centrifugation (Speed Vac SC110; Thermo Savant, Holbrook, NY, USA), 
then brought to a final volume of 100 μL by reconstituting in 0.1% formic acid.
Glycopeptides in the reconstituted preparations were desalted and enriched by solid-phase 
extraction (SPE) using a zwitterionic hydrophilic interaction liquid chromatography (ZIC-
HILIC) stationary phase in a micropipette tip format (Protea Biosciences, Somerset, NJ, 
USA). Formic acid was acquired from Sigma-Aldrich; HPLC grade acetonitrile was 
acquired from Fisher Scientific (Fair Lawn, NJ, USA); and HPLC grade water was acquired 
from Burdick and Jackson (Muskegon, MI, USA). SPE was carried out by first wetting the 
ZIC-HILIC tips in water, then equilibrating in 80% acetonitrile with 0.1% formic acid. Next, 
4 μL of reconstituted aqueous digest was added to 16 μL of acetonitrile, and the resulting 
mixture of reconstituted digest in 80% acetonitrile was loaded onto the ZIC-HILIC SPE tip. 
The stationary phase was then rinsed in 80% acetonitrile with 0.1% formic acid. Finally, the 
desalted and enriched glycopeptides were eluted into 0.1% formic acid.
Mass Spectrometry and Ion Mobility.
All MS, MS/MS, and IM experiments were performed using a quadrupole time-of-flight 
mass spectrometer (Q-TOF-MS) equipped with a traveling wave IM cell71–74 and the 
capability to perform both CID and ETD based MS/MS experiments75, 76 (Synapt G2-S 
HDMS; Waters Corporation, Manchester, UK). For sample introduction by nano-
electrospray ionization (nESI), tapered glass emitters were fabricated in-house from melting 
point capillaries (1.5 – 1.8 × 100 mm; Corning Pyrex, Corning, NY, USA) using a vertical 
micropipette puller (David Kopf Instruments, Tujunga, CA, USA). Approximately 5 – 10 μL 
of each purified N-glycopeptide preparation was transferred to an emitter using a fine-point 
syringe (Hamilton, Reno, NV, USA). The emitter was then placed on a home-built holder 
designed to mate to the commercial nESI source of the instrument, while also placing the 
sample solution within the emitter in contact with a platinum wire that delivered the 
necessary DC potential. An emitter voltage of 0.6 – 1.2 kV was applied to initiate nESI. The 
sampling cone potential and the source DC offset were each set to 10 V, the ion source block 
temperature was held at 80 – 100°C, and the flow of nitrogen cone gas was maintained at 50 
L/h.
Negatively charged radical reagent ions for ET reactions were generated by glow discharge 
ionization of 1,4-dicyanobenzene (Sigma-Aldrich) as previously described.75, 76 Vapors of 
the reagent were swept from a reservoir and through the hollow discharge pin by a 25 
mL/min flow of nitrogen make-up gas, and the discharge current was set to 30 – 50 μA. 
Quadrupole-selected reagent ions were stored in the trap region (i.e., pre-IM) stacked ring 
ion guide (SRIG) with a refill duration of 0.1 s and a refill interval of 1.0 s. The pressure in 
the trap cell was maintained at 5.0 – 6.0 × 10−2 mbar by a 12 – 14 mL/min flow of helium 
bath gas, and the RF amplitude applied to the trap cell SRIG was set to 450 – 500 V. 
Quadrupole-selected analyte ions were then directed to the trap cell. The trap cell traveling 
DC wave velocity was set to 300 m/s, while the height of this pulse was adjusted to 
modulate the reagent ion / analyte ion co-confinement time. The ion-ion interaction time was 
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minimized by application of a 1.5 V wave height (thus preventing ET reactions), or 
maximized by application of a 0.1 V wave height (thus facilitating ET reactions).
Separation of unreacted precursor ions and their corresponding charge-reduced ET products 
was carried out in the IM cell SRIG, which was held at a pressure 3.1 – 3.5 mbar by a 40 
mL/min flow of nitrogen drift gas to the main body of the cell. The entrance interface region 
of the cell was maintained at a pressure of 1.2 – 1.4 × 10−3 mbar by a 150 mL/min flow of 
helium. The RF amplitude applied to the IM SRIG was set to 250 – 300 V, while the IM cell 
traveling DC wave velocity was set between 650 – 1200 m/s with a wave height between 25 
– 40 V, depending on the analyte. Ion packets were delivered to the IM cell from the trap cell 
using a 200 – 500 μs gating pulse and a trap DC bias (i.e., the potential difference between 
trap cell and the IM cell) of 25 – 35 V, depending on the analyte.
IM-separated precursor ions and ET product ions were caused to undergo CID and ETD, 
respectively, through vibrational activation in the transfer region (i.e., post-IM) SRIG. Ions 
exiting the IM cell were accelerated into the transfer cell through a potential difference 
(ΔUVA) of 25 – 45 V, depending on the analyte. The pressure in the transfer cell was 
maintained at 1.6 – 1.8 × 10−2 mbar by a 0.5 – 0.6 mL/min flow of argon collision gas, and 
the RF amplitude applied to the transfer cell SRIG was set to 350 – 380 V. The traveling DC 
wave applied to the transfer SRIG had a velocity of between 110 – 200 m/s and a height of 
4.0 – 5.0 V. Ions exiting the transfer cell were then analyzed by TOF-MS over the range of 
m/z 50 – 3000.
Data Processing and Presentation.
MassLynx 4.1 (Waters) was used for instrument control, data acquisition, and rudimentary 
MS data processing (summing scans, smoothing spectra, etc.). DriftScope 2.7 (Waters) was 
used for basic handling of IM data, including extraction of mass spectra corresponding to 
selected drift time windows. Further analysis and visualization of IM and MS data was 
carried out using purpose-built software tools written and executed in IGOR Pro 6 
(WaveMetrics, Lake Oswego, OR, USA). Peak assignment and annotation of MS/MS 
spectra was conducted in accord with the Roepstorff / Fohlman and Domon / Costello 
nomenclatures for polypeptide and oligosaccharide fragmentations, respectively.77, 78 When 
applying these fragment ion naming systems, glycan fragments were assigned using 
uppercase letters, while peptide fragments were assigned using lowercase letters. Precursor 
ion cleavage maps were rendered using standard one-letter amino acid abbreviations and the 
monosaccharide symbology promulgated by Varki et al. and the Consortium for Functional 
Glycobiology.79, 80 Non-symbolic monosaccharide abbreviations were also used for the 
monosaccharides xylose (Xyl), fucose (Fuc), mannose (Man), galactose (Gal), N-
acetylglucosamine (GlcNAc), and N-acetylneuraminic acid (NeuAc).
Results
Overview.
The schematic flowchart shown in Figure 1 briefly illustrates the sequence of events 
employed to obtain IM-resolved CID and ETD spectra from a single packet of N-
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glycopeptide ions. In short, quadrupole-selected analyte and reagent ions were allowed to 
interact such that a portion of the initial analyte ion population was converted to charge-
reduced radical analyte ions. The resulting mixture of analyte ions undergoing either no 
reaction (NR) or electron transfer (ET) was then pulsed into the IM cell, where the two 
components were readily separated in drift time due to their different charge states. As the 
NR and ET ions exited the IM cell, they were subjected to vibrational activation (VA) by 
acceleration through a DC offset (ΔUVA) and subsequent collisions with argon gas. This 
resulted in the generation of two fragment ion populations detected by TOF-MS: those 
arising from CID of the initial, unreacted analyte ions; and those resulting from 
supplementally-activated ETD of the charge-reduced radical analyte ions. Because the two 
intact ion populations were temporally resolved by IM, the corresponding groups of 
fragment ions were likewise formed at different times. This ET-IM-VA sequence of events 
thus allowed the two distinct dissociation spectra to be disentangled according to apparent 
drift time.
HRP, BRB, CTL, and BSF were chosen as model glycoproteins for this study because each 
has been well studied with respect to their glycosylation, which collectively encompasses a 
wide range of N-glycan types including paucimannosidic (HRP and CTL), high mannose 
(BRB), and complex-type (BSF) N-glycans. Additionally, trypsinolysis of these 
glycoproteins results in glycopeptides with well-varied amino acid sequences about the 
glycosylation site, both in terms of length and composition. Finally, N-glycopeptides from 
the model glycoproteins discussed here have been previously studied by other research 
groups using both CID and ETD, thus allowing the present approach to be compared to 
relevant published examples as discussed in the succeeding sections. Taken together, the 
chosen analytes provided a diverse set attributes of well-suited to a proof-of-concept study 
on the application of IM-resolved CID and ETD for the analysis of N-linked glycopeptides.
Analysis of an N-Glycopeptide from HRP.
The first N-glycopeptide studied by sequential IM-resolved stages of CID and ETD was 
derived from HRP (UniProtKB P00433). This glycopeptide harbored a paucimannosidic N-
glycan, and had the overall composition 184NVGLNR189 + GlcNAc2 Man3 Fuc1 Xyl1 
(1841.79 u). The corresponding [M+2H]2+ ion (m/z = 921.89) was quadrupole selected and 
subjected to ET-IM-VA as described above. ET to the initial precursor ion generated a 
population of the charge-reduced product [M+2H]+• (m/z = 1843.79). Ions exiting the IM 
cell were then energized using ΔUVA = 25 V. The resultant IM-MS heat map shown in 
Figure 2a exhibited two major drift time bands corresponding to CID of the [M+2H]2+ ion 
(the region labeled dt1) and ETD of the [M+2H]+• ion (the region labeled dt2). Some ion 
signal was also noted outside of the two major drift time bands (i.e., between drift times of 
about 4–8 ms). This was attributed to some proportion of the ion population undergoing 
direct ETD, prior to IM separation. While this should be acknowledged as a potential 
complication, these pre-IM fragments represented a small fraction of the total ion intensity 
and did not obscure clear delineation of the CID and ETD spectra according to drift time. 
Extraction of the m/z and relative intensity data from the dt1 band resulted in the mass 
spectrum provided in Figure 2b. The spectrum was consistent with the expected CID 
behavior of this glycopeptide, providing complete coverage of the glycan connectivity 
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through a series of 11 fragment ions arising from Y-type glycosidic cleavages. 
Complementarily, extraction of m/z and intensity data from the dt2 region of the heat map 
provided the mass spectrum shown in Figure 2c. This ETD spectrum covered four of the five 
possible N-Cα peptide backbone cleavages (i.e., 80% sequence coverage) by virtue of the z2 
through z5 fragments. Interestingly, the ETD behavior of this glycopeptide deviates from a 
general trend noted by Desaire and coworkers, in which c-series ions tend to be predominant 
in the ETD spectra of N-glycopeptides harboring the glycan near the C-terminus (and 
likewise for z-series ions when the glycan is located near the N-terminus).81 In the present 
case, the low initial charge state of the HRP glycopeptide ion (z = 2+), coupled with the 
absence of basic amino acid side chains N-terminal of the glycosylation site, may have 
preferentially favored the formation of fragments that retained the highly basic C-terminal 
arginine residue (i.e., z ions). Cleavage of the oligosaccharide moiety was not apparent in the 
ETD spectrum. The observed CID and ETD fragment ions were mapped onto diagrams of 
the HRP N-glycopeptide in Figures 2d and 2e, respectively. The overall MS/MS coverage of 
the glycopeptide structure was found to be quite consistent with previously published CID 
and ETD spectra for the same precursor ion (including the abundant series of z-type ions 
present in the ETD spectrum).82
Analysis of an N-Glycopeptide from BRB.
A high mannose N-glycopeptide generated by trypsinolysis of BRB (UniProtKB P61823) 
was next considered. With an overall composition of58SRNLTKDR65 + GlcNAc2 Man5 
(2204.96 u), this glycopeptide bore an N-glycan consisting of seven neutral monosaccharide 
residues. While in this respect the oligosaccharide moiety was similar to that of the HRP 
glycopeptide, the two glycans also differed in that the HRP glycan was comprised of four 
different monosaccharides (GlcNAc, Man, Fuc, and Xyl), while the BRB glycan was 
comprised of only two different monosaccharides (GlcNAc and Man). This rendered the 
BRB glycan of greater molecular weight, yet lower compositional complexity. The BRB and 
HRP glycopeptides also differed in the lengths of their polypeptide chains (eight vs. six 
amino acid residues, respectively). The [M+3H]3+ ion (m/z = 735.99) was quadrupole 
selected and underwent sub-stoichiometric ET reaction to yield a mixture of the unreacted 
precursor ion and the [M+3H]2+• ion (m/z = 1103.99). IM separation and collisional 
activation of these ions (ΔUVA = 25 V) produced the results summarized in Figure 3. The 
two major drift time bands appearing in the IM-MS heat map (Figure 3a) were well-
resolved, readily allowing extraction of the individual fragmentation spectra arising from 
CID (Figure 3b) and ETD (Figure 3c). As in the previous example, some ETD product ions 
formed prior to introduction to the IM separator were apparent in the heat map (i.e., in the 
drift time region of 7 ms and greater); however, these again accounted for a relatively minor 
fraction of the total ion signal and did not materially complicate the analysis. Among these, 
a low abundance yet noticeable grouping of signals observed in Figure 3a with drift times in 
the 12 – 14 ms range and m/z values of 1500 – 1600. One potential explanation for these 
fragments is that they arose from dissociation of a lower mobility (i.e., doubly charge-
reduced) ET product; however, no direct evidence for the [M+3H]+•• ion was found. 
Alternatively, this grouping of fragments may simply have similar mobilities and arose from 
pre-IM ETD. Regardless of the origin of these minor fragments, they also appeared in the 
dt2 band ETD spectrum, and thus did not provide any additional analytical information. The 
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CID spectrum afforded complete glycosidic coverage of the GlcNAc2 Man5 N-glycan 
(Figure 3d). This was realized through a series of Y ions involving sequential loss of all five 
Man residues, eventually leading to the Y2 fragment. This series of fragments was observed 
in both the triply-charged and doubly-charged states. The Y1 fragment (SRNLTKDR + 
GlcNAc) was also observed as a doubly-charged ion. Meanwhile, the ETD spectrum 
furnished 10 peptide backbone fragment ions (c2-c3; c5; c7; z1-z6) that collectively covered 
six of the seven possible N-Cα cleavages for 85.7% sequence coverage (Figure 3e). The 
consecutive fragment ion pairs c2-c3 and z5-z6 allowed explicit site localization of the N-
glycan, while no evidence of glycan fragmentation was detected in the ETD spectrum. This 
duplexed approach yielded CID and ETD spectra that conveyed essentially the same 
structural information as those found in previous, more conventional studies of BRB 
glycopeptides.49, 50, 83–85 The cited examples for comparison included analytes in which the 
GlcNAc2 Man5 N-glycan was linked to the SRNLTKDR peptide chain (as studied here), as 
well as the SRNLTK peptide chain (as more frequently noted in the literature), and also 
encompasses precursor ions in the z = 2+ and z = 3+ charge states.
Analysis of an N-Glycopeptide from CTL.
The next tryptic N-glycopeptide for study was obtained from CTL (UniProtKB P83410). 
With the overall composition 100 SKPAQGYGYLGVFNNSK116 + GlcNAc2 Man3 Fuc1 
Xyl1 (2999.33 u), this analyte was considerably larger than the previously considered 
examples; however, the paucimannosidic oligosaccharide modifying this glycopeptide was 
identical in structure to that present on the HRP glycopeptide. Thus, the CTL glycopeptide 
primarily differed from the HRP and BRB glycopeptides in the substantially greater length 
of the polypeptide chain (17 amino acid residues). Importantly, while there were two 
asparagine residues present within the peptide sequence of this analyte, only one of these 
occurred in the context of a consensus sequon for N-glycosylation (NXS or NXT, where X is 
any amino acid, proline excepted). Thus, N113 was the only site of glycosylation. 
Quadrupole selection of the [M+3H]3+ ion (m/z = 1000.78) followed by reaction with ET 
reagent ions resulted in the formation of charge-reduced [M+3H]2+• product ions (m/z = 
1501.17). Post-activation of the IM-resolved NR and ET ions (ΔUVA = 40 V) yielded the 
characteristic IM-MS drift time vs. m/z heat map with two horizontal bands of fragment 
ions, each occurring within a unique region of apparent ion mobility space (Figure 4a). 
Unlike the comparatively smaller glycopeptides previously examined, this IM-MS heat map 
was free of any appreciable pre-IM ETD fragmentation. The glycosidic topology of the 
glycan group was fully represented in the CID spectrum (Figure 4b), with a series of doubly-
charged fragments demonstrating stepwise monosaccharide losses which ultimately revealed 
the unmodified peptide as the Y0 fragment. While not shown in Figure 4b, a comparable 
series of triply-charged Y ions was observed over a lower range of m/z, but provided no new 
information (and have thus been omitted from Figure 4b in the interest of clarity). The ETD 
spectrum (Figure 4c) was largely comprised of a contiguous series of c-type ions (c3-c13), 
collectively accounting for 11 of the 15 available N-Cα cleavage products (i.e., not 
considering the c2 cleavage N-terminal to the proline residue, which does not yield a 
fragment upon scission). This corresponds to production of 73.3% of the possible c ions, or 
an overall peptide sequence coverage of 68.8%. The presence of a predominant series of c 
ions was consistent with a general trend noticed by Desaire and coworkers, in which c-type 
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ions were found to be the major ETD fragments for peptides with N-linked glycosites 
localized to the C-terminus.81 As in the previous examples, the ETD spectrum was devoid of 
any ions corresponding to glycan cleavage or loss. A diagram of the fragments observed in 
both the CID and ETD spectra is provided in Figure 4d, where the information obtained by 
means of the ET-IM-VA experimental sequence can be seen to compare favorably with those 
obtained by other researchers using separate stages of CID and ETD.86, 87
Analysis of an N-Glycopeptide from BSF.
The final model N-glycopeptide studied here was a tryptic fragment of BSF (UniProtKB 
P12763) that harbored a triantennary, trisialylated complex-type N-linked oligosaccharide 
structure. The overall composition of this glycopeptide was 
72RPTGEVYDIEIDTLETTCHVLDPTPLANCSVR103 + GlcNAc5 Man3 Gal3 NeuAc3 
(6,531.77 u). With 14 monosaccharide residues and 32 amino acid residues, this analyte was 
significantly more massive and compositionally heterogeneous than any of the model N-
glycopeptides discussed in the preceding sections. Selection and ET reaction of the [M
+5H]5+ (m/z = 1307.36) led to the formation of a charge-reduced ET product ion, [M
+5H]4+• (m/z = 1634.20), as well as a doubly charge-reduced, even-electron ET product ion, 
[M+5H]3+•• (m/z = 2178.94). IM sorting of the resultant ion population was carried out, with 
subsequent vibrational activation accomplished with ΔUVA = 45 V. While the band of 
fragment ions generated by CID of the NR precursor ions was well-isolated, the single ET 
and double ET products were somewhat overlapped in drift time. This result was not entirely 
unexpected, as the relative difference in charge between two successive charge states (and 
the corresponding contribution to differences in mobility) decreases as the charge state 
increases. Regardless of this overlap in drift time, two distinct regions of IM drift time were 
defined which contained either unreacted precursor ions and fragments thereof (dt1), or a 
mixture of single and double ET products (dt2) and their resulting fragments (Figure 5a). No 
apparent contribution from direct ETD prior to IM separation was noted. The CID spectrum 
(Figure 5b) was prominently populated by a series of 14 triply-charged Y-type 
fragmentation products that were informative as to the stepwise deconstruction of the N-
glycan, down to the reducing terminal GlcNAc residue (Y1 fragment). Some of the same 
fragments were also observable as quadruply-charged ions at lower m/z (though for clarity 
these are not shown in Figure 5b). Examination of the ETD spectrum (Figure 5c) allowed 
assignment of 15 c and z fragment ions (c2-c12; c15; z1-z3), which in aggregate covered 15 
out of 27 (or, 55.6%) of the N-Cα bonds able to be productively cleaved (i.e., ignoring 
cleavages N-terminal to the three proline residues). The overall sequence coverage was 
48.4%. The cleavage map provided in Figure 5d summarizes the information conveyed by 
both the CID and ETD spectra. Notably, the ETD spectrum of the BSF glycopeptide also 
exhibited a single Y-type loss of a NeuAc residue. Among the analytes studied here, this 
was the only example of a CID-like glycan fragmentation occurring as a result of 
supplementally-activated ETD; however, this result is perhaps unsurprising given the 
tendency of NeuAc residues to undergo facile elimination under even gentle activation 
conditions.88, 89 Ultimately, the appearance of this fragment did not interfere with 
interpretation of the ETD spectrum. This example also illustrates that the ET-IM-VA scheme 
can be applied to even large N-glycopeptides containing particularly labile terminal 
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monosaccharides with minimal complication of the ETD spectrum by purely vibrational 
activation / dissociation processes.
Notably, previous efforts to obtain useful ETD spectra for this glycopeptide, and other 
glycoforms thereof, have generally met with limited success. For instance, attempts by 
Novotny and coworkers to generate ETD fragments from the same glycopeptide as the [M
+4H]4+ precursor ion yielded no peptide backbone fragments upon ETD.49 Another effort 
by Desaire and coworkers focused on the non-sialylated analog of this glycopeptides in the 
[M+4H]4+, [M+5H]5+, and [M+6H]6+ charge states.81 While the [M+6H]6+ precursor ion 
with the highest of these charges states yielded a rich ETD spectrum covering the majority 
of the peptide sequence, significant cleavage of the glycan moiety through collisionally-
activated processes was also reported. ETD of the [M+5H]5+ ion produced eight peptide c 
and z fragments along the peptide backbone (though several or the ions assigned had very 
low signal-to-noise ratios), as well as eight generally more abundant fragments arising from 
cleavage or loss of the glycan due to vibrational activation / dissociation. In the same study, 
the [M+4H]4+ yielded no useful product ions when ETD was attempted. Given this context, 
the ability ET-IM-VA results for the BSF glycopeptide are particularly encouraging. Not 
only was this approach able to produce an informative CID spectrum, but also an ETD 
spectrum with 55.6% peptide sequence coverage and only a single sialic acid loss. This 
improved performance apparent in the present work is likely attributable to the added 
vibrational activation step, which is likely to bring about informative dissociation processes 
in cases where a pure ETD experiment (i.e., with no vibrational activation) might not 
succeed.
Conclusions
Here, we demonstrate the use of IM to temporally disperse mass-selected precursor ions and 
their corresponding ET products and thus enable rapid sequential acquisition of high-quality 
CID and ETD spectra for protonated N-linked glycopeptide ions. The IM dimension allows 
the two fragmentation spectra to be cleanly disentangled from one another, thus simplifying 
interpretation. Moreover, this approach allows the large fraction of precursor ions that fail to 
undergo ET reactions to be productively utilized for acquiring a CID spectrum, rather than 
being sacrificed to the generally low conversion efficiency and fragmentation efficiency of 
typical ETD experiments. The model N-glycopeptide ions examined spanned a range of 
polypeptide sequences, oligosaccharide compositions and structures, charge states, and 
molecular weights. The capacity to successfully address this gamut of analytes suggests that 
the method could be generalized to an even greater assortment of N-glycopeptides.
This analytical approach takes advantage of two key characteristics of the ET product ions. 
First, under the conditions of these experiments, the ET product ions are sufficiently stable 
to survive the approximately 10 ms IM separation with little or no direct ETD – an 
advantage from the standpoint of partitioning the CID and ETD fragmentation events in 
time. The significant lifetime of the charge-reduced radical species may be attributable in 
part to collisional cooling in the trap region SRIG, which is operated at elevated pressure 
when ET reactions are desired (this relaxes analyte and reagent ions to the radial center of 
the cell, thus increasing the opportunity for ion-ion chemistry to occur). Second, the ΔUVA 
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values suitable for supplemental activation of ET product ions conveniently coincide with 
those that result in rich and informative CID spectra for the unreacted precursor ions. While 
the two processes have different vibrational energy requirements, these can be 
simultaneously satisfied by a single ΔUVA since the different charge states of the NR and ET 
ions result in different kinetic energies prior to collisional activation (i.e., the NR ions with n 
charges experience more energetic collisions than the ET ions with n-1 charges). 
Furthermore, the optimum ΔUVA appears to scale roughly with precursor ion m/z. This 
suggests that the approach could be extensible to glycoproteomic workflows including on-
line chromatographic separations. One conceivable workflow would involve mass selection 
of putative glycopeptide ions in a manner independent of fragmentation information (such as 
carbohydrate oxonium ions produced by CID) using mass defect targeting.90–95 The ΔUVA 
could then be set in a data-dependent manner according the precursor ion m/z. Such 
multiplexed approaches that take advantage of useful physicochemical properties of 
glycopeptides while efficiently leveraging complementary dissociation pathways will be 
essential to expanding the accessible scope of glycoproteomic research. The use of IM to 
duplex the acquisition of CID and ETD spectra demonstrates significant potential to 
contribute to these endeavors.
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Figure 1. 
A pictorial representation of the ET-IM-VA experiment as applied to a model N-linked 
glycopeptide from HRP (a key to the monosaccharide symbols provided in the inset). The 
initial precursor ion with n positive charges is quadrupole (Q) selected, then transiently co-
confined with negatively charged radical reagent ions (not shown). The precursor ions 
undergoing either no reaction (NR) or an electron transfer (ET) reaction are then separated 
by ion mobility (IM), which partitions the unreacted precursor ions (higher mobility) from 
the charge-reduced ET products (lower mobility). The two mobility-sorted ion populations, 
having drift times of dt1 and dt2 respectively, are next subjected to vibrational activation 
(VA) as they exit the mobility cell. This results in collision-induced dissociation (CID) of the 
unreacted precursor ions, while also providing supplemental activation that brings about 
electron transfer dissociation (ETD) of the charge-reduced species. Due to the distinct drift 
times of the NR and ET ion packets, the two dissociation experiments are temporally 
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resolved. All resulting fragment ions are analyzed by time-of-flight mass spectrometry 
(TOF-MS).
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Figure 2. 
ET-IM-VA analysis of the model N-glycopeptide derived from HRP. The IM-MS heat map is 
shown in (a), with dashed boxes highlighting the fragment ion populations arising from CID 
(dt1) and ETD (dt2). The CID spectrum extracted from the boxed dt1 region is given in (b), 
while the ETD spectrum extracted from the boxed dt2 region is given in (c). Insets in (a) – 
(c) summarize the experimental sequence corresponding to each plot. Cleavage maps 
summarizing the observed CID (d) and ETD (e) fragments are also provided, and are 
accompanied by a key to the monosaccharide symbols (inset). Note that in (a) the fragment 
ions aligned with the dt1 band at m/z > 1100 are the singly-charged equivalents of their 
doubly-charged analogs seen at m/z < 1100. These redundant fragment ions were omitted 
from (b) for clarity.
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Figure 3. 
ET-IM-VA analysis of the model N-glycopeptide derived from BRB. The IM-MS heat map 
is shown in (a), with dashed boxes highlighting the fragment ion populations arising from 
CID (dt1) and ETD (dt2). The CID spectrum extracted from the boxed dt1 region is given in 
(b), while the ETD spectrum extracted from the boxed dt2 region is given in (c). Insets in (a) 
– (c) summarize the experimental sequence corresponding to each plot. Cleavage maps 
summarizing the observed CID (d) and ETD (e) fragments are also provided, and are 
accompanied by a key to the monosaccharide symbols (inset).
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Figure 4. 
ET-IM-VA analysis of the model N-glycopeptide derived from CTL. The IM-MS heat map 
is shown in (a), with dashed boxes highlighting the fragment ion populations arising from 
CID (dt1) and ETD (dt2). The CID spectrum extracted from the boxed dt1 region is given in 
(b), while the ETD spectrum extracted from the boxed dt2 region is given in (c). Insets in (a) 
– (c) summarize the experimental sequence corresponding to each plot. A cleavage map 
summarizing the observed CID and ETD fragments is given in (d), and is accompanied by a 
key to the monosaccharide symbols (inset).
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Figure 5. 
ET-IM-VA analysis of the model N-glycopeptide derived from BSF. The IM-MS heat map is 
shown in (a), with dashed boxes highlighting the fragment ion populations arising from CID 
(dt1) and ETD (dt2). The CID spectrum extracted from the boxed dt1 region is given in (b), 
while the ETD spectrum extracted from the boxed dt2 region is given in (c). Insets in (a) – 
(c) summarize the experimental sequence corresponding to each plot. A cleavage map 
summarizing the observed CID and ETD fragments is given in (d), and is accompanied by a 
key to the monosaccharide symbols (inset).
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